IRIS
FORCONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.791
EU - Europa 6.942
AS - Asia 4.531
SA - Sud America 1.057
AF - Africa 288
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 10
Totale 26.631
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.668
CN - Cina 1.681
GB - Regno Unito 1.671
RU - Federazione Russa 1.291
SG - Singapore 1.220
IE - Irlanda 1.008
BR - Brasile 860
UA - Ucraina 819
FR - Francia 518
SE - Svezia 445
HK - Hong Kong 437
IT - Italia 429
VN - Vietnam 427
DE - Germania 348
KR - Corea 267
FI - Finlandia 220
ZA - Sudafrica 186
BD - Bangladesh 124
IN - India 84
AR - Argentina 58
CA - Canada 53
EC - Ecuador 40
IQ - Iraq 39
MX - Messico 38
TR - Turchia 38
NL - Olanda 29
NG - Nigeria 28
PK - Pakistan 28
ID - Indonesia 25
AT - Austria 23
PL - Polonia 23
VE - Venezuela 23
UZ - Uzbekistan 21
ES - Italia 20
JP - Giappone 20
CO - Colombia 19
PY - Paraguay 17
SA - Arabia Saudita 17
MA - Marocco 16
CL - Cile 15
BE - Belgio 14
AU - Australia 12
IL - Israele 11
KE - Kenya 11
CZ - Repubblica Ceca 10
EU - Europa 10
LT - Lituania 10
PH - Filippine 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
HR - Croazia 9
JO - Giordania 9
TN - Tunisia 9
UY - Uruguay 9
GR - Grecia 8
MY - Malesia 8
PE - Perù 8
AZ - Azerbaigian 7
DZ - Algeria 7
JM - Giamaica 7
AL - Albania 6
BO - Bolivia 6
TT - Trinidad e Tobago 6
CI - Costa d'Avorio 5
ET - Etiopia 5
NP - Nepal 5
OM - Oman 5
PT - Portogallo 5
TH - Thailandia 5
BA - Bosnia-Erzegovina 4
HN - Honduras 4
IR - Iran 4
KG - Kirghizistan 4
LU - Lussemburgo 4
PA - Panama 4
PS - Palestinian Territory 4
RO - Romania 4
SN - Senegal 4
CH - Svizzera 3
CR - Costa Rica 3
KZ - Kazakistan 3
LV - Lettonia 3
MD - Moldavia 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
BH - Bahrain 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
KH - Cambogia 2
MK - Macedonia 2
MM - Myanmar 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AI - Anguilla 1
Totale 26.613
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Southend 1.468
Ashburn 1.136
Dallas 1.123
Woodbridge 1.012
Dublin 1.004
Seattle 899
Houston 782
Wilmington 762
Cambridge 732
Singapore 660
Jacksonville 659
Chandler 555
Santa Clara 532
Hong Kong 430
Moscow 406
Ann Arbor 366
Beijing 353
Hefei 293
Seoul 264
San Jose 225
Princeton 223
Nanjing 214
Siena 202
The Dalles 179
Johannesburg 167
Ho Chi Minh City 146
Lauterbourg 123
Los Angeles 106
Council Bluffs 100
Hanoi 92
San Diego 87
Nanchang 80
Boardman 79
São Paulo 75
Helsinki 73
Buffalo 70
Shenyang 61
Columbus 57
New York 55
Redondo Beach 45
London 44
Milan 40
San Mateo 40
Hebei 39
Rio de Janeiro 37
Changsha 35
Shanghai 34
Jiaxing 31
Norwalk 30
Dong Ket 29
Orem 29
Da Nang 28
Frankfurt am Main 28
San Francisco 28
Tianjin 28
Abuja 27
Kunming 27
Chicago 25
Flanders 25
Toronto 25
Bengaluru 23
Falls Church 23
Menlo Park 23
Düsseldorf 22
Ningbo 22
Belo Horizonte 21
Brasília 21
Zhengzhou 21
Nuremberg 20
Tashkent 20
Brooklyn 18
Jinan 18
Curitiba 17
Guayaquil 17
Hangzhou 17
Guangzhou 16
Haiphong 16
Munich 16
Tokyo 16
Warsaw 16
Rome 15
Baghdad 13
Phoenix 13
Brussels 12
Cape Town 12
Dhaka 12
Goiânia 12
Mexico City 12
Montreal 12
Quito 12
Washington 12
Lappeenranta 11
Philadelphia 11
Porto Alegre 11
Taizhou 11
Campinas 10
Guarulhos 10
Amsterdam 9
Denver 9
Totale 19.338
Salva come PNG Salva come JPEG
Nome #
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 311
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 290
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 289
BRAF mutations in hairy-cell leukemia 277
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 272
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 265
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 248
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage 248
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 242
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 241
Alternative methods of cladribine administration 239
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 238
The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells 234
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 229
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia 229
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 228
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 226
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 226
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 226
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis 224
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation 222
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 220
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 218
Emerging drugs in chronic myelogenous leukaemia 217
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 216
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 216
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia 216
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 216
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 214
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma 214
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 213
The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL 212
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 212
Towards the pharmacotherapy of hairy cell leukaemia 208
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 208
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 206
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia 206
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 206
Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10 205
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 205
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 205
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort 204
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 204
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia 203
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 202
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 202
Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing 202
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 201
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 201
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 201
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia 200
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 200
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK 198
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 198
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 197
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis 196
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array 196
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 196
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 195
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 195
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 194
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 193
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3 191
Predicting the clinical course of Hodgkin lymphoma 191
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism 189
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 189
Bcr-abl peptides for chronic myeloid leukemia. 188
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation 187
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 186
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 183
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 183
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance 183
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses 181
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 179
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 178
Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes 178
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 178
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study 178
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 176
Origins of the malignant clone in typical Waldenstrom's macroglobulinemia 174
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia 173
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome 172
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 172
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 171
IL-4 enhances expression and function of surface IgM in CLL cells 171
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas 169
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome 169
The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia 167
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 167
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 166
Hairy cell leukaemia: biological and clinical overview from immunogenetic insights 166
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 165
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 165
STING activation reverses lymphoma-mediated resistance to antibody immunotherapy 165
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity 165
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 165
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition 164
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas 164
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency 162
Three years of ibrutinib in CLL 162
Totale 20.247
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.183
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.183
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021161 0 0 0 0 0 0 0 0 0 0 0 161
2021/20221.565 109 261 50 96 71 54 86 49 87 194 165 343
2022/20232.071 156 118 308 288 217 441 33 154 241 24 57 34
2023/20241.289 67 32 66 121 30 374 448 6 7 16 9 113
2024/20253.341 89 173 218 156 455 203 73 208 274 149 313 1.030
2025/20266.903 629 1.267 876 823 1.030 301 650 324 260 330 265 148
Totale 26.784